Table 1.

Patients characteristics and tumor volume measurement

Patient no.	Age	Sex	Tumor side	Previous treatment		Age group (years)	Baseline volume (cm3)	3rd month volume (cm3)	6th month volume (cm3)	3rd month ratio (%)*	6th month ratio (%)*
				Type	Time before bevacizumab (months)
1	38	F	Left	No	-	≥25	1.15	0.8	0.64	70	56†
2	28	F	Left	SRS	113	≥25	1.67	1.54	1.8	92†	108
3	39	F	Right	Surgical excision	127	≥25	0.92	0.82	0.81	89	88†
	39	F	Left	Surgical excision	161	≥25	3.17	2.53	2.75	80†	87
4	45	F	Left	No	-	≥25	1.54	1.23	1.32	80†	86
5	41	F	Right	Surgical excision	13	≥25	0.49	0.43	0.5	88†	102
	41	F	Left	No	-	≥25	0.94	0.57	0.63	61†	67
6	33	F	Right	No	-	≥25	0.24	0.16	0.2	67†	83
	33	F	Left	SRS	62	≥25	1.53	1.37	1.2	90	78†
7	18	F	Right	SRS	11	<25	4.7	3.77	4	80†	85
	18	F	Left	No	-	<25	2.75	2.6	3.28	95†	119
8	18	M	Right	No	-	<25	0.81	0.73	0.82	90†	101
	18	M	Left	No	-	<25	2.25	2.36	2.54	105‡	113
9	24	F	Right	No	-	<25	1.08	1.32	NA	122‡	NA
	24	F	Left	No	-	<25	1.67	1.71	NA	102‡	NA
10	12	F	Right	SRT	9	<25	16.16	14.21	16.54	88†	102
	12	F	Left	No	-	<25	9.68	9.11	10.23	94†	106

Cases with radiologic response (20% and above reduction in volume) are shown in bold.

^*Ratio of tumor volume from the baseline volume in percentage,

^†Maximum volume reduction achieved,

^‡Tumors did not show any reduction of volume, SRS: Stereotactic radiosurgery, SRT: Stereotactic radiation therapy.